1. Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next generation. Cell, 2011. 144(5): p. 646-74.
2. Cancer Genome Atlas Research, N., Comprehensive molecular characterization of gastric adenocarcinoma. Nature, 2014. 513(7517): p. 202-9.
3. Storchova, Z. and D. Pellman, From polyploidy to aneuploidy, genome instability and cancer. Nat Rev Mol Cell Biol, 2004. 5(1): p. 45-54.
4. Storchova, Z. and C. Kuffer, The consequences of tetraploidy and aneuploidy. J Cell Sci, 2008. 121(Pt 23): p. 3859-66.
5. Fisher, R., L. Pusztai, and C. Swanton, Cancer heterogeneity: implications for targeted therapeutics. British Journal Of Cancer, 2013. 108: p. 479.
6. Heng, H.H., et al., Chromosomal instability (CIN): what it is and why it is crucial to cancer evolution. Cancer Metastasis Rev, 2013. 32(3-4): p. 325-40.
7. Alsina, M., I. Gullo, and F. Carneiro, Intratumoral heterogeneity in gastric cancer: a new challenge to face. Ann Oncol, 2017. 28(5): p. 912-913.
8. Lee, H.E., et al., Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur J Cancer, 2013. 49(6): p. 1448-57.
9. Yang, J., et al., Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. Cell Biochem Biophys, 2012. 62(1): p. 221-8.
10. Duelli, D.M., et al., A primate virus generates transformed human cells by fusion.The Journal of Cell Biology, 2005. 171(3): p. 493-503.
11. Brito, D.A. and C.L. Rieder, Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr Biol, 2006. 16(12): p. 1194-200.
12. Shi, Q. and R.W. King, Chromosome nondisjunction yields tetraploid rather than aneuploid cells in human cell lines. Nature, 2005. 437(7061): p. 1038-42.
13. Daniels, M.J., et al., Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. Science, 2004. 306(5697): p. 876-9.
14. Fujiwara, T., et al., Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature, 2005. 437(7061): p. 1043-7.
15. Galipeau, P.C., et al., 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci U S A, 1996. 93(14): p. 7081-4.
16. Olaharski, A.J., et al., Tetraploidy and chromosomal instability are early events during cervical carcinogenesis. Carcinogenesis, 2006. 27(2): p. 337-43.
17. Arteaga, C.L., et al., Treatment of HER2-positive breast cancer: current status and future perspectives. Nature Reviews Clinical Oncology, 2012. 9(1): p. 16-32.
18. Bang, Y.J., et al., Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro- oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010. 376(9742): p. 687-97.
19. Satoh, T., et al., Lapatinib plus paclitaxel versus paclitaxel alone in the second- line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. J Clin Oncol, 2014. 32(19): p. 2039-49.
20. Thuss-Patience, P.C., et al., Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol, 2017. 18(5): p. 640-653.
21. Verma, S., et al., Trastuzumab emtansine for HER2-positive advanced breast cancer. New England Journal of Medicine, 2012. 367(19): p. 1783-1791.
22. Holland, A.J. and D.W. Cleveland, Losing balance: the origin and impact of aneuploidy in cancer. EMBO Rep, 2012. 13(6): p. 501-14.
23. King, R.W., When 2+2=5: the origins and fates of aneuploid and tetraploid cells.Biochim Biophys Acta, 2008. 1786(1): p. 4-14.
24. Ganem, N.J., Z. Storchova, and D. Pellman, Tetraploidy, aneuploidy and cancer.Curr Opin Genet Dev, 2007. 17(2): p. 157-62.
25. Sturgill, E.G., et al., Kinesin-5 inhibitor resistance is driven by kinesin-12. J Cell Biol, 2016. 213(2): p. 213-27.
26. Weil, D., et al., Targeting the kinesin Eg5 to monitor siRNA transfection in mammalian cells. Biotechniques, 2002. 33(6): p. 1244-8.
27. Naito, Y., et al., CRISPRdirect: software for designing CRISPR/Cas guide RNA with reduced off-target sites. Bioinformatics, 2015. 31(7): p. 1120-3.
28. Cong, L., et al., Multiplex genome engineering using CRISPR/Cas systems.Science, 2013. 339(6121): p. 819-23.
29. He, J., et al., PTEN regulates EG5 to control spindle architecture and chromosome congression during mitosis. Nat Commun, 2016. 7: p. 12355.
30. Iimori, M., et al., Phosphorylation of EB2 by Aurora B and CDK1 ensures mitotic progression and genome stability. Nat Commun, 2016. 7: p. 11117.
31. Saijo, T., et al., Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimitotic agents combined with platinum chemotherapy. Lung Cancer, 2006. 54(2): p. 217-25.
32. Otsu, H., et al., Gastric Cancer Patients with High PLK1 Expression and DNA Aneuploidy Correlate with Poor Prognosis. Oncology, 2016. 91(1): p. 31-40.
33. Ando, K., et al., High expression of BUBR1 is one of the factors for inducing DNA aneuploidy and progression in gastric cancer. Cancer Sci, 2010. 101(3): p. 639- 45.
34. Furuya, T., et al., Relationship between chromosomal instability and intratumoral regional DNA ploidy heterogeneity in primary gastric cancers. Clin Cancer Res, 2000. 6(7): p. 2815-20.
35. Hiddemann, W., et al., Convention on nomenclature for DNA cytometry. Committee on Nomenclature, Society for Analytical Cytology. Cancer Genet Cytogenet, 1984. 13(2): p. 181-3.
36. Schneider, C.A., W.S. Rasband, and K.W. Eliceiri, NIH Image to ImageJ: 25 years of image analysis. Nat Methods, 2012. 9(7): p. 671-5.
37. Tsuda, Y., et al., Mitotic slippage and the subsequent cell fates after inhibition of Aurora B during tubulin-binding agent-induced mitotic arrest. Sci Rep, 2017. 7(1): p. 16762.
38. Hauf, S., et al., The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol, 2003. 161(2): p. 281-94.
39. Rath, O. and F. Kozielski, Kinesins and cancer. Nat Rev Cancer, 2012. 12(8): p. 527-39.
40. Kapoor, T.M., et al., Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. J Cell Biol, 2000. 150(5): p. 975-88.
41. Sawin, K.E., et al., Mitotic spindle organization by a plus-end-directed microtubule motor. Nature, 1992. 359(6395): p. 540-3.
42. Mayer, T.U., et al., Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science, 1999. 286(5441): p. 971-4.
43. Vitale, I., et al., Multipolar mitosis of tetraploid cells: inhibition by p53 and dependency on Mos. EMBO J, 2010. 29(7): p. 1272-84.
44. Roschke, A.V., et al., Stable Karyotypes in Epithelial Cancer Cell Lines Despite High Rates of Ongoing Structural and Numerical Chromosomal Instability. Neoplasia (New York, N.Y.), 2002. 4(1): p. 19-31.
45. Landry, J.J., et al., The genomic and transcriptomic landscape of a HeLa cell line.G3 (Bethesda), 2013. 3(8): p. 1213-24.
46. Macville, M., et al., Comprehensive and definitive molecular cytogenetic characterization of HeLa cells by spectral karyotyping. Cancer Res, 1999. 59(1):p. 141-50.
47. Castedo, M., et al., Apoptosis regulation in tetraploid cancer cells. EMBO J, 2006.25(11): p. 2584-95.
48. Thompson, S.L. and D.A. Compton, Proliferation of aneuploid human cells is limited by a p53-dependent mechanism. J Cell Biol, 2010. 188(3): p. 369-81.
49. Blangy, A., et al., Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell, 1995. 83(7): p. 1159-69.
50. Cahu, J., et al., Phosphorylation by Cdk1 Increases the Binding of Eg5 to Microtubules In Vitro and in Xenopus Egg Extract Spindles. PLoS ONE, 2008. 3(12): p. e3936.
51. Chee, M.K. and S.B. Haase, B-cyclin/CDKs regulate mitotic spindle assembly by phosphorylating kinesins-5 in budding yeast. PLoS Genet, 2010. 6(5): p. e1000935.
52. Sawin, K.E. and T.J. Mitchison, Mutations in the kinesin-like protein Eg5 disrupting localization to the mitotic spindle. Proc Natl Acad Sci U S A, 1995. 92(10): p. 4289-93.
53. Avunie-Masala, R., et al., Phospho-regulation of kinesin-5 during anaphase spindle elongation. J Cell Sci, 2011. 124(Pt 6): p. 873-8.
54. Tanenbaum, M.E., et al., Kif15 cooperates with eg5 to promote bipolar spindle assembly. Curr Biol, 2009. 19(20): p. 1703-11.
55. She, Z.-Y. and W.-X. Yang, Molecular mechanisms of kinesin-14 motors in spindle assembly and chromosome segregation. Journal of Cell Science, 2017. 130(13):p. 2097-2110.
56. Mountain, V., et al., The kinesin-related protein, HSET, opposes the activity of Eg5 and cross-links microtubules in the mammalian mitotic spindle. J Cell Biol, 1999. 147(2): p. 351-66.
57. Norris, S.R., et al., Microtubule minus-end aster organization is driven by processive HSET-tubulin clusters. Nat Commun, 2018. 9(1): p. 2659.
58. Kim, N. and K. Song, KIFC1 is essential for bipolar spindle formation and genomic stability in the primary human fibroblast IMR-90 cell. Cell Struct Funct, 2013. 38(1): p. 21-30.
59. Jin, Q., et al., High Eg5 expression predicts poor prognosis in breast cancer.Oncotarget, 2017. 8(37): p. 62208-62216.
60. Liu, C., et al., Eg5 Overexpression Is Predictive of Poor Prognosis in Hepatocellular Carcinoma Patients. Dis Markers, 2017. 2017: p. 2176460.
61. Tao, W., et al., Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell, 2005. 8(1): p. 49-59.
62. Kapitein, L.C., et al., The bipolar mitotic kinesin Eg5 moves on both microtubules that it crosslinks. Nature, 2005. 435(7038): p. 114-8.
63. Chen, Y. and W.O. Hancock, Kinesin-5 is a microtubule polymerase. Nat Commun, 2015. 6: p. 8160.
64. Sercin, O., et al., Transient PLK4 overexpression accelerates tumorigenesis in p53-deficient epidermis. Nat Cell Biol, 2016. 18(1): p. 100-10.
65. Ganem, N.J., S.A. Godinho, and D. Pellman, A mechanism linking extra centrosomes to chromosomal instability. Nature, 2009. 460(7252): p. 278-82.
66. van Ree, J.H., et al., Pten regulates spindle pole movement through Dlg1-mediated recruitment of Eg5 to centrosomes. Nat Cell Biol, 2016. 18(7): p. 814-21.
67. Rapley, J., et al., The NIMA-family kinase Nek6 phosphorylates the kinesin Eg5 at a novel site necessary for mitotic spindle formation. J Cell Sci, 2008. 121(Pt 23):p. 3912-21.
68. Liu, Y., et al., Protein Phosphatase 2A (PP2A) Regulates EG5 to Control Mitotic Progression. Sci Rep, 2017. 7(1): p. 1630.
69. Abarbanel, J., et al., Cytogenetic studies in patients with gastric cancer. World J Surg, 1991. 15(6): p. 778-82.
70. Tsushima, K., et al., Correlation of DNA ploidy, histopathology, stage and clinical outcome in gastric carcinoma. Surg Oncol, 1992. 1(1): p. 17-25.
71. Daigo, K., et al., Characterization of KIF11 as a novel prognostic biomarker and therapeutic target for oral cancer. 2017.
72. Kato, T., et al., Personalized siRNA-Nanoparticle Systemic Therapy using Metastatic Lymph Node Specimens Obtained with EBUS-TBNA in Lung Cancer. Molecular Cancer Research, 2018. 16(1): p. 47.
73. Cutsem, E.V., et al., Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). Journal of Clinical Oncology, 2009. 27(18S): p. LBA4509-LBA4509.
74. Gravalos, C. and A. Jimeno, HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol, 2008. 19(9): p. 1523-9.
75. He, C., et al., Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. World J Gastroenterol, 2013. 19(14): p. 2171-8.
76. Kim, K.C., et al., Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol, 2011. 18(10): p. 2833-40.
77. Otsu, H., et al., Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer. Anticancer Res, 2015. 35(4): p. 2441-6.
78. Guarneri, V., et al., Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. Ann Oncol, 2013. 24(12): p. 2990-4.
79. Mittendorf, E.A., et al., Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res, 2009. 15(23): p. 7381-8.
80. Ishimine, Y., et al., Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent? Case Reports in Gastrointestinal Medicine, 2015. 2015: p. 132030.
81. Pietrantonio, F., et al., HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. Int J Cancer, 2016. 139(12): p. 2859-2864.
82. Seo, S., et al., Loss of HER2 positivity after anti-HER2 chemotherapy in HER2- positive gastric cancer patients: Results of GASTric cancer HER2 reassessment study 3 (GASTHER3). Journal of Clinical Oncology, 2017. 35(4_suppl): p. 27-27.
83. Baselga, J., et al., Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res, 1998. 58(13): p. 2825-31.
84. Fujimoto-Ouchi, K., et al., Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol, 2007. 59(6): p. 795-805.
85. Kwak, E.L., et al., Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. Cancer Discov, 2015. 5(12): p. 1271-81.
86. Fuse, N., et al., Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients. Gastric Cancer, 2016. 19(1): p. 183- 91.
87. Nagatsuma, A.K., et al., Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. Gastric Cancer, 2015.18(2): p. 227-38.
88. Abrahao-Machado, L.F. and C. Scapulatempo-Neto, HER2 testing in gastric cancer: An update. World J Gastroenterol, 2016. 22(19): p. 4619-25.
89. Hofmann, M., et al., Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology, 2008. 52(7): p. 797-805.
90. Ruschoff, J., et al., HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch, 2010. 457(3): p. 299-307.
91. Hanna, W.M., et al., HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol, 2014. 27(1):p. 4-18.
92. Varella-Garcia, M., et al., EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J Clin Pathol, 2009. 62(11): p. 970-7.
93. Verma, S., et al., Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med, 2012. 367(19): p. 1783-91.
94. Yamashita-Kashima, Y., et al., Importance of formalin fixing conditions for HER2 testing in gastric cancer: immunohistochemical staining and fluorescence in situ hybridization. Gastric Cancer, 2014. 17(4): p. 638-647.
95. Chi, F., et al., HER2 induces cell proliferation and invasion of non-small-cell lung cancer by upregulating COX-2 expression via MEK/ERK signaling pathway. Onco Targets Ther, 2016. 9: p. 2709-16.
96. Eladdadi, A. and D. Isaacson, A mathematical model for the effects of HER2 overexpression on cell proliferation in breast cancer. Bull Math Biol, 2008. 70(6):p. 1707-29.
97. Baselga, J., et al., HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (Williston Park), 1997. 11(3 Suppl 2):p. 43-8.
98. Muss, H.B., et al., c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med, 1994. 330(18): p. 1260-6.
99. Jia, Y.-X., et al., The coexpression and prognostic significance of c-MET, fibroblast growth factor receptor 2, and human epidermal growth factor receptor 2 in resected gastric cancer: a retrospective study. OncoTargets and therapy, 2016. 9: p. 5919-5929.
100. Stahl, P., et al., Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. BMC Gastroenterol, 2015. 15: p. 7.
101. Gullo, I., et al., Minimum biopsy set for HER2 evaluation in gastric and gastro- esophageal junction cancer. Endoscopy International Open, 2015. 3(2): p. E165- E170.
102. Huang, S.C., et al., HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance. Gastric Cancer, 2016. 19(1): p. 176-82.
103. Purcell, J.W., et al., Activity of the Kinesin Spindle Protein Inhibitor Ispinesib (SB-715992) in Models of Breast Cancer. Clinical Cancer Research, 2010. 16(2):p. 566.
104. Komlodi-Pasztor, E., D.L. Sackett, and A.T. Fojo, Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale. Clin Cancer Res, 2012. 18(1): p. 51-63.
論文の公開元へ
